source
- BioNTech spends $205 million on FDA priority review voucher to accelerate oncology pipelineBioNTech has agreed to pay $205 million to acquire an FDA priority review voucher, a tool that can shorten the agency's standard review period from ten months to six months. The voucher was previo…
- Flagship-backed Valo Health merges with Montai Therapeutics to boost AI-driven drug pipelineValo Health and Montai Therapeutics announced they will combine under the Valo brand, creating a larger AI-focused biotech aimed at accelerating early-stage drug discovery. Valo, launched in 2020…